Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 08, 2024 07:00 ET | Source: Autolus Therapeutics plc

Autolus Announces Pricing of Underwritten Offering

Autolus Announces Pricing of Underwritten Offering
February 08, 2024 05:45 ET | Source: Autolus Therapeutics plc; BioNTech SE

BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs

BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs
January 23, 2024 07:00 ET | Source: Autolus Therapeutics plc

Autolus Therapeutics announces publication in ACS Chemical Biology

Autolus Therapeutics announces publication in ACS Chemical Biology
January 22, 2024 07:00 ET | Source: Autolus Therapeutics plc

Autolus Therapeutics announces acceptance of Biologics License Application for obecabtagene autoleucel (obe-cel) as a potential treatment for relapsed/refractory Adult B-cell Acute Lymphoblastic Leukemia (ALL)

Autolus Therapeutics announces acceptance of BLA for obe-cel as a potential treatment for relapsed/refractory adult ALL
January 10, 2024 07:00 ET | Source: Autolus Therapeutics plc

Autolus Therapeutics announces the appointment of Robert W. Azelby to its Board of Directors

Autolus Therapeutics announces the appointment of Robert W. Azelby to its Board of Directors
December 22, 2023 07:00 ET | Source: Autolus Therapeutics plc

Autolus Therapeutics Announces Changes to its Board of Directors

Autolus Therapeutics Announces Changes to its Board of Directors
December 09, 2023 20:30 ET | Source: Autolus Therapeutics plc

Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023

Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023
November 27, 2023 07:00 ET | Source: Autolus Therapeutics plc

Autolus Therapeutics Submits Biologics License Application to U.S. Food and Drug Administration for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (ALL)

Autolus Therapeutics Submits Biologics License Application to U.S. Food and Drug Administration for obecabtagene autoleucel (obe-cel)
November 15, 2023 07:00 ET | Source: Autolus Therapeutics plc

Autolus Therapeutics to Host Analyst / Investor event at the American Society of Hematology (ASH) Annual Meeting 2023

Autolus Therapeutics to Host Analyst / Investor event at the American Society of Hematology (ASH) Annual Meeting 2023
November 06, 2023 07:00 ET | Source: Autolus Therapeutics plc

Autolus Therapeutics announces participation in upcoming conferences

Autolus Therapeutics announces participation in upcoming conferences